Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up

M. Domenica Cappellini, Mohamed Bejaoui, Leyla Agaoglu, Duran Canatan, Marcello Capra, Alan Cohen, Guillermo Drelichman, Marina Economou, Slaheddine Fattoum, Antonis Kattamis, Yurdanur Kilinc, Silverio Perrotta, Antonio Piga, John B. Porter, Louis Griffel, Victor Dong, Joan Clark, Yesim Aydinok

Blood (2011) 118 (4): 884–893.

https://doi.org/10.1182/blood-2010-11-316646

Published: 2011

Includes: Supplemental data

Journal Articles

Long-Term Safety and Efficacy of Deferasirox (Exjade ® ) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years

Elliott Vichinsky, MD, Francoise Bernaudin, MD, Gian Luca Forni, MD, Renee Gardner, MD, Kathryn Hassell, MD, Matthew M. Heeney, MD, Baba Inusa, MD, Abdullah Kutlar, MD, Peter A. Lane, MD, Liesl Mathias, MD, John B. Porter, MD, Cameron K Tebbi, MD, Felicia L. Wilson, MD, Louis Griffel, MD, Wei Deng, PhD, Vanessa Giannone, BSN, Thomas D. Coates, MD

Blood (2010) 116 (21): 845.

https://doi.org/10.1182/blood.V116.21.845.845

Published: 2010

Journal Articles

Deferasirox Improves Liver Pathology In β-Thalassemia Patients with Transfusional Iron Overload

Yves Deugnier, MD, Bruno Turlin, MD, PhD, Victor Dong, MD, Vanessa Giannone, BSN, Yiyun Zhang, PhD, Louis Griffel, MD, Pierre Brissot, MD

Blood (2010) 116 (21): 4274.

https://doi.org/10.1182/blood.V116.21.4274.4274

Published: 2010

Journal Articles

A Phase I/II, Open-Label, Dose-Escalation Trial of Once-Daily Oral Chelator Deferasirox to Treat Iron Overload in HFE-Related Hereditary Hemochromatosis: Final Results of the Core Study.

Pradyumna D. Phatak, Pierre Brissot, Herbert Bonkovsky, Mark Wurster, Lawrie Powell, Claus Niederau, Paul Adams, Wolfgang Stremmel, Louis Griffel, Nicola Lynch, Oliver Schoenborn-Kellenberger, Antonello Pietrangelo

Blood (2009) 114 (22): 1514.

https://doi.org/10.1182/blood.V114.22.1514.1514

Published: 2009

Journal Articles

Efficacy and Safety of Deferasirox (Exjade®) in Patients with β-Thalassemia Major Treated for up to 5 Years.

M. Domenica Cappellini, Silverio Perrotta, Leyla Agaoglu, Yesim Aydinok, Marcello Capra, Duran Canatan, Guillermo Drelichman, Yurdanur Kilinc, Carmelo Magnano, John B. Porter, Antonio Piga, Louis Griffel, Darlene Lagrone, Joan Clark, Antonis Kattamis

Blood (2009) 114 (22): 4063.

https://doi.org/10.1182/blood.V114.22.4063.4063

Published: 2009

NARROW

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up

Long-Term Safety and Efficacy of Deferasirox (Exjade ® ) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years

Deferasirox Improves Liver Pathology In β-Thalassemia Patients with Transfusional Iron Overload

A Phase I/II, Open-Label, Dose-Escalation Trial of Once-Daily Oral Chelator Deferasirox to Treat Iron Overload in HFE-Related Hereditary Hemochromatosis: Final Results of the Core Study.

Efficacy and Safety of Deferasirox (Exjade®) in Patients with β-Thalassemia Major Treated for up to 5 Years.

Email alerts

ASH Publications

American Society of Hematology

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up

Long-Term Safety and Efficacy of Deferasirox (Exjade ® ) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years

Deferasirox Improves Liver Pathology In β-Thalassemia Patients with Transfusional Iron Overload

A Phase I/II, Open-Label, Dose-Escalation Trial of Once-Daily Oral Chelator Deferasirox to Treat Iron Overload in HFE-Related Hereditary Hemochromatosis: Final Results of the Core Study.

Efficacy and Safety of Deferasirox (Exjade®) in Patients with β-Thalassemia Major Treated for up to 5 Years.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only